Best for
Mobile

Posted
Arix Bioscience plc is a biotechnology business based in the UK. Arix Bioscience shares (ARIX.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Arix Bioscience employs 15 staff and has a trailing 12-month revenue of around £23.5 million.
Best for
Mobile
Best for
Low-cost
Best for
All rounder
Best for
Beginners
Latest market close | N/Ap |
---|---|
52-week range | 57p - 234p |
50-day moving average | 203.2576p |
200-day moving average | 128.4078p |
Wall St. target price | 295.33p |
PE ratio | 13.0357 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | 14p |
Other fees may apply. Your capital is at risk.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Arix Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arix Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arix Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Arix Bioscience shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Arix Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £14.9 million.
The EBITDA is a measure of a Arix Bioscience's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | £23.5 million |
---|---|
Operating margin TTM | 61.7% |
Gross profit TTM | £-58,136,000 |
Return on assets TTM | 3.71% |
Return on equity TTM | 7.54% |
Profit margin | 77.56% |
Book value | 1.924p |
Market capitalisation | £247.5 million |
TTM: trailing 12 months
We're not expecting Arix Bioscience to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Arix Bioscience's shares have ranged in value from as little as 57p up to 234p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Arix Bioscience's is 1.5866. This would suggest that Arix Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Subscribe to trending stock alerts for a chance to win
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.